CRBU earnings analysis
What we found in CRBU's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Caribou’s Q2 revenue declined to $1.499 million from approximately $2 million sequentially and $3 million year over year, while the diluted loss improved to $(0.24) per share from $(0.58) in the prior-year quarter. Liquidity of $113.8 million is expected to fund the current operating plan through the end of 2027, but the company is still evaluating financing alternatives to fully fund ANTLER-3. The filing provided no new numeric EPS or revenue guidance and disclosed no material changes to existing risk factors.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declined Sequentially and YoY
- Q2 revenue was $1.499 million, down from approximately $2 million in Q1 2026 and approximately $3 million in Q2 2025, indicating sequential and year-over-year contraction.
- Per-Share Loss Improved
- Reported GAAP loss was $(0.24) per diluted share versus $(0.26) in Q1 2026 and $(0.58) in Q2 2025, an improvement of $0.02 sequentially and $0.34 year over year.
- Gross Margin Remained 100%
- Gross margin was 100.0%, consistent with the company’s recent quarterly history, although the revenue base remained only $1.499 million.
- Cash Runway Extends Through 2027
- Management said $113.8 million of cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund the current operating plan through the end of 2027.
- Disclosure Controls Effective
- Management reported that disclosure controls were effective as of June 30, 2026, and that there were no changes in internal control during the quarter that materially affected or were reasonably likely to materially affect those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- ANTLER-3 Funding Requirement
- The company is evaluating financing options to fully fund the planned ANTLER-3 trial despite stating that $113.8 million of liquidity supports the current operating plan through the end of 2027; additional funding may therefore be required for the trial.
- Continuing Operating Losses
- Caribou remains loss-making, reporting a $(0.24) diluted EPS loss in Q2 2026 while generating only $1.499 million of revenue, underscoring continuing dependence on cash resources or future financing.
- Revenue and Clinical Execution Risk
- Revenue declined to $1.499 million from approximately $3 million in Q2 2025, while the company continues to depend on development-program execution and clinical progress to support future commercial potential.
- No New Risk-Factor Updates
- The 10-Q states there were no material changes to the risk factors previously disclosed in the Form 10-K; therefore, no newly added quantified risk factor was identified in this filing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.24
- Gross margin
- 100.0%
What they said about what is next.
No numeric revenue or EPS range was provided. Management stated that $113.8 million of cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund the current operating plan through the end of 2027, while the company evaluates options to fully fund the planned ANTLER-3 trial.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Caribou Biosciences reported Q1 2026 revenue of $2.4 million, consistent with the prior year, while reducing its net loss to $25.1 million from $40 million in the same quarter last year. The company significantly cut…
- 10-K · March 5, 2026
- Caribou has narrowed to a two-program strategy focused on allogeneic CAR‑T candidates vispa‑cel (anti‑CD19) and CB‑011 (anti‑BCMA) built on its proprietary chRDNA genome‑editing platform and has taken cost actions…
- 10-K · March 10, 2025
- Caribou Biosciences is a clinical-stage CRISPR genome‑editing company focused on four allogeneic CAR‑T programs (CB‑010, CB‑011, CB‑012 and CB‑011) leveraging its chRDNA technology to enable multiplex edits and armoring…
- 10-Q · November 6, 2024
- Caribou reported licensing and collaboration revenue of $2,024,000 for the quarter ended September 30, 2024, down sharply from $23,662,000 in the year-ago quarter. The company recorded a three-month net loss of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CRBU makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever